NASDAQ:EPIX - ESSA Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $28.80
  • Forecasted Upside: 6.35 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$27.08
▼ -0.15 (-0.55%)
1 month | 3 months | 12 months
Get New ESSA Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EPIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EPIX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$28.80
▲ +6.35% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for ESSA Pharma in the last 3 months. The average price target is $28.80, with a high forecast of $50.00 and a low forecast of $9.00. The average price target represents a 6.35% upside from the last price of $27.08.
Buy
The current consensus among 5 polled investment analysts is to buy stock in ESSA Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/18/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/16/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/14/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/10/2021Piper SandlerInitiated CoverageOverweight$50.00Low
i
3/4/2021Piper SandlerInitiated CoverageOverweight$50.00Medium
i
3/3/2021HC WainwrightLower Price TargetBuy$36.00 ➝ $32.00Low
i
Rating by J. Pantginis at HC Wainwright
2/25/2021HC WainwrightLower Price TargetBuy$36.00 ➝ $32.00Low
i
Rating by J. Pantginis at HC Wainwright
2/12/2021Bloom BurtonReiterated RatingBuyN/A
i
Rating by D. Martin at Bloom Burton
2/11/2021OppenheimerBoost Price TargetOutperform$20.00 ➝ $36.00Low
i
2/11/2021HC WainwrightBoost Price TargetBuy$17.00 ➝ $36.00Low
i
Rating by J. Pantginis at HC Wainwright
1/14/2021OppenheimerBoost Price TargetOutperform$9.00 ➝ $20.00Low
i
1/11/2021HC WainwrightBoost Price TargetBuy$10.00 ➝ $17.00High
i
Rating by J. Pantginis at HC Wainwright
11/2/2020Jefferies Financial GroupInitiated CoverageBuy$17.00High
i
8/10/2020OppenheimerReiterated RatingBuy$9.00Medium
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
7/15/2020OppenheimerInitiated CoverageBuy$9.00Medium
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
6/22/2020OppenheimerReiterated RatingBuy$8.00High
i
5/24/2020Bloom BurtonReiterated RatingBuy$9.00High
i
5/15/2020HC WainwrightReiterated RatingBuyMedium
i
5/8/2020OppenheimerReiterated RatingBuy$8.00Low
i
10/24/2019OppenheimerInitiated CoverageOutperform$8.00Low
i
5/17/2019HC WainwrightReiterated RatingBuyHigh
i
2/15/2019HC WainwrightReiterated RatingBuyLow
i
3/26/2018HC WainwrightInitiated CoverageBuy$0.70Medium
i
Rating by J. Pantginis at HC Wainwright
1/18/2018Bloom BurtonUpgradeHold ➝ BuyHigh
i
Rating by D. Martin at Bloom Burton
9/12/2017Bloom BurtonDowngradeBuy ➝ HoldLow
i
Rating by D. Martin at Bloom Burton
8/3/2017Dawson JamesReiterated RatingBuyHigh
i
Rating by R. Wasserman at Dawson James
5/18/2017Bloom BurtonReiterated RatingBuyLow
i
Rating by D. Martin at Bloom Burton
2/17/2017Noble FinancialInitiated CoverageBuy$9.00N/A
i
(Data available from 4/14/2016 forward)
ESSA Pharma logo
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $27.08
$26.67
$27.85

50 Day Range

MA: $29.12
$25.43
$32.08

52 Week Range

Now: $27.08
$3.76
$32.69

Volume

90,004 shs

Average Volume

362,574 shs

Market Capitalization

$914.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.96

Frequently Asked Questions

What sell-side analysts currently cover shares of ESSA Pharma?

The following equities research analysts have issued reports on ESSA Pharma in the last year: Bloom Burton, HC Wainwright, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., and Piper Sandler.
View the latest analyst ratings for EPIX.

What is the current price target for ESSA Pharma?

5 Wall Street analysts have set twelve-month price targets for ESSA Pharma in the last year. Their average twelve-month price target is $28.80, suggesting a possible upside of 6.4%. Piper Sandler has the highest price target set, predicting EPIX will reach $50.00 in the next twelve months. Bloom Burton has the lowest price target set, forecasting a price of $9.00 for ESSA Pharma in the next year.
View the latest price targets for EPIX.

What is the current consensus analyst rating for ESSA Pharma?

ESSA Pharma currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EPIX will outperform the market and that investors should add to their positions of ESSA Pharma.
View the latest ratings for EPIX.

What other companies compete with ESSA Pharma?

How do I contact ESSA Pharma's investor relations team?

ESSA Pharma's physical mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The company's listed phone number is 778-331-0962 and its investor relations email address is [email protected] The official website for ESSA Pharma is www.essapharma.com.